Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024

医薬品有力企業シリーズ:主要医薬品製造受託機関(CMO)分析

◆タイトル:Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024
◆商品コード:VISION411062
◆調査・発行会社:visiongain
◆発行日:2014年9月
◆ページ数:330
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single userGBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept licence (2-5 users)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、世界の主要医薬品製造受託機関(CMO)について調査・分析し、市場概観、ヨーロッパ市場、主要先進国市場、中国市場、インド市場における医薬品受託製造企業データなどをお届けいたします。

・サマリー
・イントロダクション:医薬品製造受託市場
・主な欧州の医薬品製造受託機関(CMO)
・その他の主要先進市場におけるCMO
・主な先進市場におけるAPIメーカー
・主な中国の医薬品製造受託企業
・主なインドの医薬品受託製造企業
・結論

[Contract manufacturing for pharma – discover top companies’ revenue prospects]
How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s new report shows you their prospects to 2024. There you discover that industry and market’s results, trends, opportunities and prospects, also with predicted revenues and profits.

Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. So what trends, technologies and opportunities most shape the future? You find out, benefiting your knowledge, decisions and authority.
That way you discover analysis on established and emerging companies across the world. Read on, then, to scan those organisations and see what their future market could be worth.

[Forecasts and other data to help you stay ahead for commercial data]
In that updated study you find analytical profiles of 30 top companies, and analyses of their overall industry. You discover historical data, market and sales shares, growth rates and revenue forecasts. See, too, qualitative analyses, business outlooks and developments.
There you gain 184 tables, 111 charts and five interviews with that industry.
Our work lets you assess the most lucrative services in outsourced drug making. That way you can stay ahead in understanding the CMO industry and market. And also benefit your research, analyses and influence. In particular, see prospects for these market segments:
• Active pharmaceutical ingredients (API) production
• Finished dosage formulations (FDF) manufacturing.
There hear how you can benefit your work, also saving time and helping you stay ahead of competitors. And the following sections highlight what our updated investigation gives you.

[Company profiles – activities, results, competition and prospects]
Our report analyses 30 leading companies. The content of each profile differs, depending on the organisation. In general, though, a profile gives you the following information:
• Overview of the company’s contract manufacturing services, including clients
• Analysis of recent financial performance – annual revenue for CMO services, operating profit and margin
• Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations
• SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2014 onwards
• Forecasting of pharmaceutical manufacturing revenue to 2024 (for 28 firms), as well as projected operating profit and margin for some companies
• Transcript of an interview by visiongain (for five companies).
Discover there what participants offer, achieve, aim for and say, helping you stay ahead.

[European contract manufacturing organisations]
First our study gives you discussions, financial analyses and commercial outlooks for 14 European CMOs, including these firms:
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Famar
• Vetter Pharma.
Discover what the future holds for those pharma service providers, including revenue outlooks to 2024. What profitability and other achievements are possible?
CMOs based in the US and Japan
Next our report shows you developments and business outlooks for seven other medical production contractors:
• Catalent Pharma Solutions
• Patheon
• Baxter BioPharma Solutions
• AbbVie Contract Manufacturing
• Pfizer CentreSource
• Daito Pharmaceutical
• Nipro Corporation.
Our work shows you where sales growth can occur. Many opportunities remain, with high, expanding revenues forecasted from 2014. You discover where prospects exist, seeing what’s possible.

[Developed-market API specialists]
You also discover outlooks for three top producers of active pharmaceutical ingredients:
• Teva API
• Esteve Química
• Euticals.
Our report shows you potentials of that industry. You see possibilities for advancing medical technology and raising business performance, with better serving of clients.

[India and China – analysis of pharma manufacturing service providers]
Our work also assesses six Indian and Chinese companies. There you discover activities and prospects of these firms:
• Dr. Reddy’s Laboratories
• Aurobindo Pharma
• Divis Laboratories
• Shandong Xinhua Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• Zhejiang Huahai Pharmaceuticals.
That way you find sales data and underlying trends, seeing what the present and future hold.

[Predictions for the worldwide pharma CMO market and submarkets]
Our report also forecasts revenues to 2024 for the world contract manufacturing industry and its main segments: APIs and FDFs.
There you see overall world revenues reaching $71bn in 2018. Our analyses reveal high sales expansion from 2014 to 2024. That work also predicts large companies and specialty healthcare firms will develop and prosper. She why, how and where, finding potentials.
In particular, biologics and biosimilars hold promise. New therapies – including antibody-drug conjugates, high potency APIs and regenerative medicines – interest CMOs and clients.
So discover opportunities and revenue predictions for outsourced production of medicines. You investigate established and rising companies, finding their potentials.

【レポートの目次】

1. Report Summary
1.1 Leading Contract Manufacturing Organisations (CMOs) Review
1.2 Leading CMOs – Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers Information
1.5 Main Questions This Report Answers
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQs)
1.9 Some Related Reports
1.10 About Visiongain
2. Introduction to Pharmaceutical Contract Manufacturing, 2014
2.1 What Services Do Contract Manufacturers Offer?
2.1.1 Why Do Firms Outsource Manufacturing?
2.1.2 What Is Driving Demand for Contract Manufacturing Services?
2.2 The Pharmaceutical Contract Manufacturing Market, 2013
2.2.1 Where is Supply and Demand Highest for Contract Manufacturing Services?
2.3 Outlook for the Pharmaceutical Contract Manufacturing Market 2014-2024
2.4 Driving and Restrictive Forces for Pharmaceutical Contract Manufacturing, 2014-2024
2.4.1 Pharmaceutical Contract Manufacturing: Market Drivers 2014-2024
2.4.2 Pharmaceutical Contract Manufacturing: Market Restraints 2014-2024
2.5 Who Are the Leading Pharmaceutical Contract Manufacturers in 2014?
3. Leading European Contract Manufacturing Organisations (CMOs), 2014
3.1 Lonza
3.1.1 Lonza Is a Leader in Biologics Manufacturing
3.1.2 Lonza Contract Manufacturing and Development: Declining Revenue, but Increased Efficiency, 2009-2013
3.1.3 Investing in Advanced Biological Drug Sectors
3.1.4 The Promise of Antibody-Drug Conjugates (ADCs)
3.1.5 Lonza and Regenerative Medicine
3.1.6 Lonza: SWOT Analysis 2014-2024
3.1.7 Biologics and Efficiency Savings Will Drive Growth in Revenue and Operating Profit for Lonza 2014-2024
3.1.8 Lonza: Company Insight
3.2 Evonik Degussa
3.2.1 Investing in API and Drug Delivery Services
3.2.2 Moderate Growth in Pharmaceutical Manufacturing Services, 2009-2013
3.2.3 Evonik Is a HPAPI Specialist
3.2.4 Evonik Continues to Grow Across All Segments
3.2.5 How Can Evonik Expand in the Pharmaceutical Contract Manufacturing Market?
3.2.6 Evonik Degussa: Revenue Forecast 2014-2024
3.3 Royal DSM
3.3.1 Marginal Revenue Growth and Rapidly Declining Operating Profit in Pharma Manufacturing 2009-2013
3.3.2 DSM Pharmaceuticals Products: Manufacturing Services 2009-2013
3.3.3 DSM Sinochem Pharmaceuticals: A World Leader in Antibacterial Manufacturing
3.3.4 DPx Holdings: A New Leader in the CMO Market
3.3.5 Investing in Biopharma Manufacturing
3.3.6 Expanding API Manufacturing
3.3.7 Generics and Biologics Are an Opportunity for Growth, 2014-2024
3.3.8 DSM Pharmaceuticals Products: Revenue Forecast 2014-2024
3.4 Boehringer Ingelheim Contract Manufacturing
3.4.1 Expanding Biopharmaceuticals Manufacturing Services in China
3.4.2 Production Through to Fill and Finished Biopharmaceuticals
3.4.3 A Track Record of Production for 28 Biopharma Products
3.4.4 Declining Revenue from Contract Manufacturing, 2009-2013
3.4.5 Pulling Out of Small Molecule API Manufacturing
3.4.6 Expanding through New Services
3.4.7 Boehringer Ingelheim Biopharmaceuticals: Opportunities for Growth 2014-2024
3.4.8 Boehringer Ingelheim: Revenue Forecast 2014-2024
3.4.9 Boehringer Ingelheim Biopharmaceuticals: Company Insight
3.5 Fareva
3.5.1 Fareva Has 35 Years’ Manufacturing Experience
3.5.2 Revenue Growth through Acquisitions: 2009-2013
3.5.3 Fareva SWOT Analysis: 2014-2024
3.5.4 Fareva Revenue Forecast: 2014-2024
3.6 Aenova Group
3.6.1 Acquisition of Haupt Creates European CMO Goliath
3.6.2 Aenova’s Ever Expanding Manufacturing Capacity
3.6.3 Aenova’s Revenue 2009-2013: Organic Growth and Acquisitions
3.6.4 Haupt Pharma Acquisition: Revenue Growth 2009-2013
3.6.5 Aenova’s Competitive Position in the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.6.6 Becoming a Leading Contract Manufacturer: Aenova Revenue and Operation Profit Forecast 2014-2024
3.7 Famar
3.7.1 Famar Is an Expert in Lyophilisation
3.7.2 Sustained Growth in Famar’s Revenue: 2009-2013
3.7.3 Expanding European Operations
3.7.4 Further Site Acquisitions Are an Opportunity for Growth 2014-2024
3.7.5 How Will Famar Perform 2014-2024?
3.8 Vetter Pharma
3.8.1 Vetter is an Injectable Manufacturing Specialist
3.8.2 Rapidly Growing Revenue in the US and Germany: 2009-2013
3.8.3 Services, Collaborations and Differentiating Factors
3.8.4 Biologics Are an Opportunity for Growth for Vetter 2014-2024
3.8.5 Vetter Outlook: Revenue Forecast 2014-2024
3.9 Almac Group
3.9.1 Almac’s Manufacturing Services
3.9.2 Almac Outpaces the Market: 2009-2013
3.9.3 Almac Adds Capacity in the UK and US
3.9.4 New Services Added 2012-2014
3.9.5 Almac Group: Contract Manufacturing Market Outlook 2014-2024
3.9.6 How Will Almac Group Perform 2014-2024?
3.10 Delpharm
3.10.1 Finished Dosage Form Manufacturing for Developed Markets
3.10.2 Delpharm: Rapid Revenue Growth Via Acquisitions, 2009-2013
3.10.3 Delpharm: Outlook and Prospects for Growth 2014-2024
3.10.4 Generics Will Drive Revenue Growth for Delpharm 2014-2024
3.11 Siegfried
3.11.1 Expanding Siegfried’s Manufacturing Footprint
3.11.2 Siegfried: Financial Performance 2009-2013
3.11.3 Expanding High Potency API Capabilities
3.11.4 Expanding Into China 2013-2014
3.11.5 Siegfried’s Characteristics Within the Contract Manufacturing Market: SWOT Analysis 2014-2024
3.11.6 Continued Revenue Growth for Siegfried 2014-2024
3.12 Corden Pharmaceutical
3.12.1 CordenPharma Has Grown through Acquisitions
3.12.2 Corden Pharmaceutical: SWOT Analysis 2014-2024
3.13 Recipharm
3.13.1 Contract Development and Manufacturing Services
3.13.2 Recipharm: Financial Performance 2009-2013
3.13.3 Recipharm Invests in Facility Expansion
3.13.4 Recipharm: Opportunities for Growth 2014-2024
3.13.5 Outlook for Recipharm: Revenue Forecast 2014-2024
3.13.6 Recipharm: Company Insight
3.14 Aesica Pharmaceuticals
3.14.1 Aesica Manufactures APIs and Finished Dosage Forms
3.14.2 Acquisitions Drive Revenue Growth But Operational Margins Have Declined, 2009-2013
3.14.3 Partnering with Academia for Innovative Solutions
3.14.4 Growth through Acquisitions and Internal Expansion
3.14.5 Aesica: Opportunities for Expansion 2014-2024
3.14.6 Forecast Aesica Financial Performance, 2014-2024
4. Other Leading Developed-Market CMOs, 2014
4.1 Catalent Pharma Solutions Is the World’s Largest CMO
4.1.1 Catalent: Manufacturing Services and Capabilities
4.1.2 Divisional Segmentation – Breaking Down Catalent’s Service
4.1.3 Revenue Growth with Improved Operational Margins: Catalent Pharma’s Performance, 2009-2013
4.1.4 Sustained Grow in Oral Products and Development Services: Catalent Pharma’s Divisional Performance, 2009-2013
4.1.5 Catalent Is Expanding its Oral Technologies Division
4.1.6 Quadrupling Biopharmaceutical Manufacturing Capacity
4.1.7 Adding New Early-Stage Development Services
4.1.8 Expansion in Japan – Growth Prospects for Catalent
4.1.9 New Business Contracts 2013-2014
4.1.10 Catalent: Opportunities for Growth 2014-2024
4.1.11 Catalent: Mild Growth in Revenue and Operating Profit 2014-2024
4.2 Patheon – FDF Manufacturer and Drug Development Services
4.2.1 Patheon – Global leader in Pharmaceutical Development Services
4.2.2 Contract Manufacturing Services at Patheon
4.2.3 Steady Revenue Growth 2009-2013
4.2.4 Formation of DPx Holdings
4.2.5 Adding New Formulations and Formulation Development Services
4.2.6 Reassessing Manufacturing Capacity
4.2.7 Patheon: SWOT Analysis 2014-2024
4.2.8 Patheon: Contract Manufacturing Revenue Forecast 2014-2024
4.2.9 Patheon: Company Insight
4.3 Baxter BioPharma Solutions
4.3.1 Baxter BioPharma is the Global Leader in Sterile Fill and Finish
4.3.2 Historic Revenue Performance 2009-2013
4.3.3 Baxter BioPharma SWOT Analysis 2014-2024
4.3.4 Baxter BioPharma Revenue Forecast 2014-2024
4.4 Nipro Corporation: Japan’s Leading CMO
4.4.1 Nipro Pharmaceutical Contract Manufacturing Capabilities
4.4.2 Nipro: Exceptional Growth in Revenue and Operating Profits 2009-2013
4.4.3 Biosimilars and Anti-Cancer Drugs Are Opportunities for Future Growth: SWOT Analysis 2014-2024
4.4.4 Nipro Revenue and Profitability Forecast 2014-2014
4.5 AbbVie Contract Manufacturing
4.5.1 AbbVie Offers Full-Service Contract Manufacturing
4.5.2 Expanding and Adding New Services: 2013-2014
4.5.3 AbbVie Contract Manufacturing: Revenue 2011-2013
4.5.4 Biologics and HPAPIs Are an Opportunity for Growth 2014-2024
4.5.5 AbbVie Contract Manufacturing Revenue Forecast 2014-2024
4.5.6 AbbVie Contract Manufacturing: Company Insight
4.6 Daito Pharmaceutical
4.6.1 Daito Has a Portfolio of More than 30 APIs
4.6.2 Rapid Growth in Revenue and Operational Profit: Daito Financial Performance 2009-2013
4.6.3 Daito Is Well-Placed for Asian Market Growth – SWOT Analysis 2014-2024
4.6.4 Sustained Growth in Revenue and Operating Profit for Daito, 2014-2024
4.7 Pfizer CentreSource
4.7.1 Pfizer CentreSource: Historic Revenue Performance, 2009-2013
4.7.2 Will Pfizer Divest CentreSource?
4.7.3 Outlook for CentreSource: Revenue Forecast 2014-2024
5. Leading Developed Market API Manufacturers, 2014
5.1 Teva API
5.1.1 API Manufacturing Services
5.1.2 Teva API: Financial Performance 2009-2013
5.1.3 Building a Footprint in Mexico, India and China
5.1.4 Teva API: SWOT Analysis 2014-2024
5.1.5 Outlook for Teva API: Revenue Forecast 2014-2024
5.2 Esteve Química
5.2.1 Esteve Química Manufactures APIs for Developed and Emerging Markets
5.2.2 Investing to Expand 2004-2013
5.2.3 Esteve Química: SWOT Analysis 2014-2024
5.3 Euticals
5.3.1 Euticals Manufactures More than 200 APIs
5.3.2 Acquisitions Drive Growth 2009-2013
5.3.3 Adding Capacity for Finished Dosage Forms
5.3.4 Asian Expansion Is an Opportunity for Growth 2014-2024
5.3.5 Euticals: Revenue Forecast 2014-2024
6. Leading Chinese Pharmaceutical Contract Manufacturers, 2014
6.1 Zhejiang Hisun Pharmaceutical
6.1.1 API Manufacturing for Markets Worldwide
6.1.2 Zhejiang Hisun’s Rapid Growth in API Revenue Grows, 2009-2013
6.1.3 Moving Into International Drug Marketing
6.1.4 Zhejiang Hisun: Opportunities for Growth 2014-2024
6.1.5 Zhejiang Hisun: Strong API Revenue Growth 2014-2024
6.2 Zhejiang Huahai Pharmaceuticals
6.2.1 Zhejiang Huahai Is a Market Leader Within the Antihypertensive API Market
6.2.2 Zhejiang Huahai: Contract Manufacturing Performance 2009-2013
6.2.3 Expanding in the US Generic Drugs Market
6.2.4 Zhejiang Huahai: SWOT Analysis, 2014
6.2.5 Zhejiang Huahai: Revenue Forecast, 2014-2024
6.3 Shandong Xinhua Pharmaceutical
6.3.1 Experience in APIs and Finished Dosage Forms
6.3.2 Shandong Xinhua: Strong Revenue Growth 2009-2013
6.3.3 Growing through Joint Ventures
6.3.4 Looking to Expand in the US and EU 2014-2024
6.3.5 Shandong Xinhua Pharmaceutical: Revenue Forecast 2014-2024
7. Leading Indian Pharmaceutical Contract Manufacturers, 2014
7.1 Aurobindo Pharma
7.1.1 API Manufacturing Services
7.1.2 Aurobindo Pharma: Steady Revenue Growth 2009-2013
7.1.3 Aurobindo Expanding Outside of Antibacterials
7.1.4 Aurobindo: Opportunities for Expansion 2014-2024
7.1.5 How Will Aurobindo’s Contract Manufacturing Division Perform 2014-2024?
7.2 Divis Laboratories
7.2.1 Divis Laboratories and the Contract Manufacturing Industry
7.2.2 Divis Laboratories: The Fastest Growing CMO 2009-2013
7.2.3 Divis Laboratories: API Manufacturing Outlook 2014-2024
7.2.4 Divis Laboratories: API Manufacturing Revenue Forecast, 2014-2024
7.3 Dr. Reddy’s Laboratories
7.3.1 API and FDF Manufacturing Services
7.3.2 Dr. Reddy’s PSAI: Strong Revenue Growth 2009-2013
7.3.3 Advancing in Complex Drug Manufacturing
7.3.4 Expanding in the European Manufacturing Market
7.3.5 Dr. Reddy’s PSAI Division: Revenue Forecast 2014-2024
8. Conclusions to Our Study
8.1 What Has Driven Growth for CMO Market Leaders in Recent Years?
8.2 Strategies for Growth: Prospects for Leading CMOs, 2014-2024
8.3 High Demand for Biopharmaceutical Manufacturing Services
8.4 Investing in Novel Technologies
8.5 Outlook for API Manufacturers

List of Tables
Table 1.1 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2013
Table 1.2 Foreign Currency Exchange Rates Used: 2013 Average Exchange Rate to $US
Table 2.1 Benefits and Drawbacks to Outsourcing Pharmaceutical Manufacturing, 2014
Table 2.2 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), 2013
Table 2.3 Contract Manufacturing Market by Leading Country: Market Size ($bn), Market Share (%), 2013
Table 2.4 Contract Manufacturing Market by Service: Market Size ($bn), Market Share (%), CAGR (%), 2013, 2018 and 2024
Table 2.5 Leading Pharmaceutical Contract Manufacturing Organisations: Rank, Revenue ($m), Market Share (%), 2013
Table 3.1 Lonza Details, 2014
Table 3.2 Selected Lonza Pharmaceutical and Biotech Manufacturing and Development Agreements, 2010-2014
Table 3.3 Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2009-2013
Table 3.4 ADCs Approved and in Late Stage Clinical Development, 2014
Table 3.5 Lonza SWOT Analysis, 2014
Table 3.6 Forecast Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2013-2018
Table 3.7 Forecast Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), 2018-2024
Table 3.8 Evonik Degussa Details, 2014
Table 3.9 Evonik Health and Nutrition: R&D and Production Sites by Region, 2014
Table 3.10 Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2009-2013
Table 3.11 Evonik Pharmaceutical Manufacturing: SWOT Analysis, 2014-2024
Table 3.12 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.13 Royal DSM Details, 2014
Table 3.14 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), Operating Profit/Loss ($m), Operating Margin (%) 2009-2013
Table 3.15 DSM Pharmaceutical Products (DPP) Division: Revenue ($m), Annual Growth (%), CAGR (%), 2009-2013
Table 3.16 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), Annual Growth (%), CAGR (%), 2009-2013
Table 3.17 DSM Pharmaceutical Manufacturing: SWOT Analysis, 2014
Table 3.18 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2018
Table 3.19 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2018-2024
Table 3.20 Boehringer Ingelheim Biopharmaceuticals Details, 2014
Table 3.21 Boehringer Ingelheim Total Pharmaceutical Manufacturing Capacity: Reactor Size and Number of Units by CMO Service, 2014
Table 3.22 Products Developed by Boehringer Ingelheim Biopharmaceuticals, 1983-2014
Table 3.23 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2009-2013
Table 3.24 Boehringer Ingelheim: SWOT Analysis, 2014
Table 3.25 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.26 Fareva Details, 2014
Table 3.27 Fareva Manufacturing Facilities, 2014
Table 3.28 Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 3.29 Fareva: SWOT Analysis, 2014
Table 3.30 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.31 Aenova Group Details, 2014
Table 3.32 Aenova Group Manufacturing Capacity by Dosage Form, 2014
Table 3.33 Aenova Group Manufacturing Facility Details, 2014
Table 3.34 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.35 Haupt Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 3.36 Aenova Group SWOT Analysis, 2014
Table 3.37 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2013-2018
Table 3.38 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2018-2024
Table 3.39 Famar Details, 2014
Table 3.40 Famar Pharmaceutical Manufacturing Facilities, 2014
Table 3.41 Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 3.42 Famar: SWOT Analysis, 2014
Table 3.43 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.44 Vetter Details, 2014
Table 3.45 Vetter Pharma Manufacturing Facilities, 2014
Table 3.46 Vetter Pharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 3.47 Vetter: SWOT Analysis, 2014
Table 3.48 Forecast Vetter Pharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.49 Almac Details, 2014
Table 3.50 Almac Pharmaceutical Manufacturing Facilities Details, 2014
Table 3.51 Almac Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.52 Almac: SWOT Analysis, 2014
Table 3.53 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2013-2018
Table 3.54 Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2018-2024
Table 3.55 Delpharm Details, 2014
Table 3.56 Delpharm: Facilities and Services, 2014
Table 3.57 Delpharm: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 3.58 Delpharm Revenue by Manufacturing Site: Revenue ($m), Share of Total Revenue (%), 2013
Table 3.59 Delpharm: SWOT Analysis, 2014
Table 3.60 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 3.61 Siegfried Details, 2014
Table 3.62 Siegfried Pharmaceutical Manufacturing Facilities Details, 2014
Table 3.63 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.64 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.65 Siegfried: SWOT Analysis, 2014
Table 3.66 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2013-2018
Table 3.67 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Annual Growth Rates (%), CAGRs (%), Operating Margin (%), 2018-2024
Table 3.68 CordenPharma Details, 2014
Table 3.69 CordenPharma Facilities and Service Details, 2014
Table 3.70 Corden Pharmaceuticals SWOT Analysis, 2014
Table 3.71 Recipharm Details, 2014
Table 3.72 Recipharm: Facility Details and Services, 2014
Table 3.73 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.74 Recipharm Manufacturing Revenue by Client Size: Revenue ($m), Share of Total Revenues (%), 2013
Table 3.75 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), Share of Total Revenues (%), 2013
Table 3.76 Recipharm: SWOT Analysis, 2014
Table 3.77 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2013-2018
Table 3.78 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2018-2024
Table 3.79 Aesica Details, 2014
Table 3.80 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 3.81 Aesica SWOT Analysis, 2014
Table 3.82 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2013-2018
Table 3.83 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2018-2024
Table 4.1 Catalent Details, 2014
Table 4.2 Catalent Facility Details, 2014
Table 4.3 Catalent Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2009-2013
Table 4.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2013
Table 4.5 Catalent Financial Performance by Division: Revenue ($m), Annual Growth Rate (%), Revenue Share (%), CAGR (%), 2009-2013
Table 4.6 Catalent Pharma SWOT Analysis, 2014
Table 4.7 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 4.8 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.9 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 4.10 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.11 Patheon Details, 2014
Table 4.12 Patheon Manufacturing Facilities, 2014
Table 4.13 Patheon Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), CAGR (%), Operating Margin (%), Annual Growth Rates (%), CAGRs (%), 2009-2013
Table 4.14 Patheon: SWOT Analysis, 2014
Table 4.15 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2013-2024
Table 4.16 Baxter BioPharma Solutions Details, 2014
Table 4.17 Baxter BioPharma Solutions: Facilities and Services Offered, 2014
Table 4.18 Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth (%), CAGR (%), 2009-2013
Table 4.19 Baxter BioPharma Solutions SWOT Analysis, 2014
Table 4.20 Forecast Baxter BioPharma Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 4.21 Nipro Pharma Details, 2014
Table 4.22 Nipro Pharmaceutical Contract Manufacturing: Annual Production Capacity, 2014
Table 4.23 Nipro Pharmaceutical Contract Manufacturing Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2009-2013
Table 4.24 Nipro Pharmaceutical Contract Manufacturing SWOT Analysis, 2014
Table 4.25 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 4.26 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.27 Abbvie Contract Manufacturing: Details, 2014
Table 4.28 Abbvie Contract Manufacturing Facility Capabilities, 2014
Table 4.29 AbbVie Pharmaceutical Manufacturing: Revenue ($m) Annual Growth Rate (%), 2011-2013
Table 4.30 Abbvie Contract Manufacturing SWOT Analysis, 2014
Table 4.31 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 4.32 Daito Pharmaceuticals: Details, 2014
Table 4.33 Daito Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rates (%), CAGR (%), 2009-2013
Table 4.34 Daito Pharmaceuticals SWOT Analysis, 2014
Table 4.35 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 4.36 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 4.37 Pfizer CentreSource Details, 2014
Table 4.38 Pfizer CentreSource: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 4.39 Pfizer CentreSource SWOT Analysis, 2014
Table 4.40 Forecast Pfizer CentreSource Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 5.1 Teva API Details, 2014
Table 5.2 Teva API: Site Acquisitions, 1980-2011
Table 5.3 Teva API: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 5.4 Teva API SWOT Analysis, 2014
Table 5.5 Forecast Teva API Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 5.6 Esteve Química Details, 2014
Table 5.7 Esteve Química SWOT Analysis, 2014
Table 5.8 Euticals Details, 2014
Table 5.9 Euticals Facility Details: Production Capacity and Key Products, 2014
Table 5.10 Euticals Cumulative Regulatory Filings by Region/Country: Filings, Share of Total (%), 2014
Table 5.11 Euticals: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 5.12 Euticals Revenue by Product Class: Revenue ($m), Share of Total (%), 2013
Table 5.13 Euticals Revenue by Region: Revenue ($m), Share of Total (%), 2013
Table 5.14 Euticals SWOT Analysis, 2014
Table 5.15 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 6.1 Zhejiang Hisun Pharmaceuticals Details, 2014
Table 6.2 Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 6.3 Zhejiang Hisun Manufacturing: SWOT Analysis, 2014
Table 6.4 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 6.5 Zhejiang Huahai Pharmaceuticals Details, 2014
Table 6.6 Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 6.7 Zhejiang Huahai Contract Manufacturing: SWOT Analysis, 2014
Table 6.8 Forecast Zhejiang Huahai Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 6.9 Shandong Xinhua Pharmaceuticals Details, 2014
Table 6.10 Shandong Xinhua Pharmaceutical Production Capacity by Dosage Form, 2014
Table 6.11 Shandong Xinhua: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 6.12 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2014
Table 6.13 Shandong Xinhua Manufacturing: SWOT Analysis, 2014
Table 6.14 Forecast Shandong Xinhua Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 7.1 Aurobindo Pharma Details, 2014
Table 7.2 Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 7.3 Aurobindo Contract Manufacturing Revenue by API Class: Revenue ($m), Revenue Share (%), 2013
Table 7.4 Aurobindo Contract Manufacturing: SWOT Analysis, 2014
Table 7.5 Forecast Aurobindo Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 7.6 Divis Laboratories Details, 2014
Table 7.7 Divis Laboratories: Facility Details, Production Capacity and Services, 2014
Table 7.8 Cumulative Divis Laboratories Drug Master File (DMF) Applications: Application by Region, Share of Total (%), 1990-2013
Table 7.9 Divis Laboratories: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 7.10 Divis Laboratories Revenue Distribution: Revenue ($m), Share of Total (%), 2013
Table 7.11 Divis Laboratories Revenue by Region: Revenue ($m), Share of Total (%), 2013
Table 7.12 Divis Laboratories Contract Manufacturing: SWOT Analysis, 2014
Table 7.13 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2013-2018
Table 7.14 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), Annual Growth Rate (%), CAGR (%), 2018-2024
Table 7.15 Dr. Reddy’s Laboratories Details, 2014
Table 7.16 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), 1987-2014
Table 7.17 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 7.18 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Applications Accepted by Region, Regional Share (%), FY 2013
Table 7.19 Dr. Reddy’s Laboratories: Contract Manufacturing Revenue ($m) by Regional Market and Revenue Share (%), FY 2013
Table 7.20 Dr. Reddy’s Laboratories: SWOT Analysis, 2014
Table 7.21 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), Annual Growth Rate (%), CAGR (%), 2013-2024
Table 8.1 Top Five Developed and Emerging Market CMOs: Combined Revenue ($bn), Annual Growth Rate (%), CAGR (%), 2009-2013
Table 8.2 CMOs by Absolute Change in Revenue ($m): Annual Revenue ($m), Absolute Change in Revenue ($m), 2009-2013
Table 8.3 Leading CMOs: Combined Annual Revenue ($bn), Annual Growth (%), Market Share (%), CAGR (%), 2013-2024
Table 8.4 Top Five Developed and Emerging Market CMOs: Combined Revenue ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2013-2024
Table 8.5 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2013-2018
Table 8.6 CMOs by Absolute Change in Revenue: Annual Revenue ($m), Absolute Change in Revenue ($m), 2018-2024


List of Figures
Figure 1.1 Important Factors for CMO Business Growth, 2014
Figure 1.2 Segmentation of Contract Manufacturing Organisations, 2014
Figure 2.1 Selected Services Contracted to CMOs by Developmental Stage, 2014
Figure 2.2 Contract Manufacturing Market by Service: Market Share (%), 2013
Figure 2.3 Contract Manufacturing Market by Leading Country: Market Share (%), 2013
Figure 2.4 Contract Manufacturing Market by Service: Market Size ($bn), 2013, 2018 and 2024
Figure 2.5 Pharmaceutical Contract Manufacturing: Drivers and Restraints, 2014-2024
Figure 3.1 Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 3.2 Lonza Custom Manufacturing by Regional Market: Revenue Share (%), 2013
Figure 3.3 Forecast Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.4 Forecast Lonza Custom Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 3.5 Evonik Health and Nutrition: R&D and Production Sites (%) by Region, 2014
Figure 3.6 Evonik Pharmaceutical Manufacturing: Revenue ($m), 2009-2013
Figure 3.7 Forecast Evonik Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.8 Royal DSM Pharmaceutical Manufacturing: Revenue ($m), Operating Profit/Loss ($m), Operating Margin (%) 2009-2013
Figure 3.9 Royal DSM Pharmaceutical Manufacturing by Division: Revenue ($m), 2009-2013
Figure 3.10 DSM Pharmaceutical Products (DPP) Division: Revenue ($m), 2009-2013
Figure 3.11 DSM Sinochem Pharmaceuticals (DSP): Revenue ($m), 2009-2013
Figure 3.12 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2013-2024
Figure 3.13 Forecast Royal DSM Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.14 Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2009-2013
Figure 3.15 Forecast Boehringer Ingelheim Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.16 Fareva Pharmaceutical Manufacturing: Revenue ($m), 2009-2013
Figure 3.17 Forecast Fareva Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.18 Aenova Group Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 3.19 Haupt Pharmaceutical Manufacturing: Revenue ($m), 2009-2013
Figure 3.20 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.21 Forecast Aenova Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 3.22 Famar Pharmaceutical Manufacturing: Revenue ($m), 2009-2013
Figure 3.23 Forecast Famar Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.24 Vetter Pharma Manufacturing: Revenue ($m), 2009-2013
Figure 3.25 Forecast Vetter Pharma Manufacturing: Revenue ($m), 2013-2024
Figure 3.26 Almac Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 3.27 Forecast Almac Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.28 Forecast Almac Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 3.29 Delpharm: Revenue ($m), 2009-2013
Figure 3.30 Delpharm Revenue by Manufacturing Site: Share of Total Revenue (%), 2013
Figure 3.31 Forecast Delpharm Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 3.32 Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 3.33 Siegfried Pharmaceutical Manufacturing Revenue by Service: API Revenue ($m), Drug Product Revenue ($m), 2009-2013
Figure 3.34 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2012
Figure 3.35 Siegfried Pharmaceutical Manufacturing Revenue by Customer Location: Revenue Share (%), 2013
Figure 3.36 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.37 Forecast Siegfried Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 3.38 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 3.39 Recipharm Manufacturing Revenue by Client: Share of Total Revenues (%), 2013
Figure 3.40 Recipharm Manufacturing Revenue Distribution: Customer Revenue ($m), 2013
Figure 3.41 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.42 Recipharm: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 3.43 Aesica Pharmaceuticals: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2009-2013
Figure 3.44 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 3.45 Aesica Pharmaceuticals: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 4.1 Catalent Facilities by Region, 2014
Figure 4.2 Catalent Facilities by Service Offered, 2014
Figure 4.3 Catalent Financial Performance: Revenue ($m)*, Operating Profit ($m)*, Operating Margin (%), 2009-2013
Figure 4.4 Catalent Financial Performance by Product Type: Revenue ($m), Revenue Share (%), 2013
Figure 4.5 Catalent Financial Performance by Division: Revenue ($m)*, 2009-2013
Figure 4.6 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 4.7 Forecast Catalent Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 4.8 Forecast Catalent Pharmaceutical Manufacturing by Division: Revenue ($m), 2013-2024
Figure 4.9 Patheon Pharmaceutical Development Projects (%) by Phase, 2014
Figure 4.10 Patheon Pharmaceutical Manufacturing Projects by Client Size: Proportion of Total Revenue (%), 2014
Figure 4.11 Patheon Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 4.12 Forecast Patheon Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 4.13 Forecast DPx Holdings Performance by Equity Partner: Revenue ($m), 2013-2024
Figure 4.14 Baxter BioPharma Manufacturing: Revenue ($m), 2009-2013
Figure 4.15 Forecast Baxter BioPharma Manufacturing: Revenue ($m), 2013-2024
Figure 4.16 Nipro Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 4.17 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 4.18 Forecast Nipro Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 4.19 AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2011-2013
Figure 4.20 Forecast AbbVie Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 4.21 Daito Pharmaceuticals Financial Performance: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 4.22 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 4.23 Forecast Daito Pharmaceutical Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 4.24 Pfizer CentreSource: Revenue ($m), 2009-2013
Figure 4.25 Forecast Pfizer CentreSource Manufacturing: Revenue ($m), 2013-2024
Figure 5.1 Teva API: Revenue ($m), 2009-2013
Figure 5.2 Forecast Teva API Manufacturing: Revenue ($m), 2013-2024
Figure 5.3 Euticals Cumulative Regulatory Filings by Region/Country: Share of Total (%), 2014
Figure 5.4 Euticals: Revenue ($m), 2009-2013
Figure 5.5 Euticals Revenue by Product Class: Share of Total Revenues (%), 2013
Figure 5.6 Euticals Revenue by Region: Share of Total Revenues (%), 2013
Figure 5.7 Forecast Euticals Pharmaceutical Manufacturing: Revenue ($m), 2013-2024
Figure 6.1 Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2009-2013
Figure 6.2 Forecast Zhejiang Hisun Contract Manufacturing: Revenue ($m), 2013-2024
Figure 6.3 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2009-2013
Figure 6.4 Zhejiang Huahai Contract Manufacturing: Revenue ($m), 2013-2024
Figure 6.5 Shandong Xinhua: Revenue ($m), 2009-2013
Figure 6.6 Shandong Xinhua Revenue Share by Geographic Region: Revenue Share (%), 1H 2014
Figure 6.7 Forecast Shandong Xinhua Manufacturing: Revenue ($m), 2013-2024
Figure 7.1 Aurobindo Contract Manufacturing: Revenue ($m), 2009-2013
Figure 7.2 Aurobindo Contract Manufacturing: Revenue Share (%), 2013
Figure 7.3 Forecast Aurobindo Contract Manufacturing: Revenue ($m), 2013-2024
Figure 7.4 Cumulative Divis Laboratories Drug Master File (DMF) Applications: Application by Region (%), 1990-2013
Figure 7.5 Divis Laboratories Contract Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2009-2013
Figure 7.6 Divis Laboratories Revenue Distribution: Revenue ($m), 2013
Figure 7.7 Divis Laboratories Revenue by Region: Share of Total (%), 2013
Figure 7.8 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2013-2018
Figure 7.9 Forecast Divis Laboratories Contract Manufacturing: Revenue ($m), Operating Profit ($m), Operating Margin (%), 2018-2024
Figure 7.10 Dr. Reddy’s Laboratories Cumulative Drug Master File (DMF) Applications: Accepted by Region (%), 1987-2014
Figure 7.11 Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2009-2013
Figure 7.12 Dr. Reddy’s Laboratories Drug Master File (DMF) Applications: Accepted Applications by Region (%), FY 2013
Figure 7.13 Dr. Reddy’s Laboratories Contract Manufacturing Revenue: Regional Revenue Share (%), FY 2013
Figure 7.14 Forecast Dr. Reddy’s Laboratories Contract Manufacturing: Revenue ($m), 2013-2024
Figure 8.1 Top Five Developed and Emerging Market CMOs: Combined Revenue ($bn), 2009-2013
Figure 8.2 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2009-2013
Figure 8.3 Leading CMOs: Combined Annual Revenue ($bn), 2013-2024
Figure 8.4 Top Five Developed and Emerging Market CMOs: Combined Revenue ($bn), 2013-2024
Figure 8.5 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2013-2018
Figure 8.6 Top Ten Global CMOs by Absolute Change in Revenue: Absolute Change in Revenue ($m), 2018-2024


【レポートのキーワード】

医薬品製造受託機関、製薬、APIメーカー

★調査レポート[医薬品有力企業シリーズ:主要医薬品製造受託機関(CMO)分析] ( Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024 / VISION411062) 販売に関する免責事項
[医薬品有力企業シリーズ:主要医薬品製造受託機関(CMO)分析] ( Pharma Leader Series : Leading Pharmaceutical Contract Manufacturing Organisations (CMOs) 2014-2024 / VISION411062) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆